<?xml version="1.0" encoding="UTF-8"?>
<p>Obesity or overweight is the primary risk factor for developing type II diabetes. Diabetes, obesity, hyperglycemia, and hypercholesterolemia, occurring together or independently, have been directly associated with cancers in the kidney, bladder, thyroid, ovary, breast, endometrium, stomach, liver, pancreas, colon, and rectum, as well as leukemia. The adoption of a healthier lifestyle is the recommended strategy to prevent overweight or obesity and avoid cancers related to these comorbidities [
 <xref rid="B128-ijms-22-00265" ref-type="bibr">128</xref>,
 <xref rid="B129-ijms-22-00265" ref-type="bibr">129</xref>,
 <xref rid="B130-ijms-22-00265" ref-type="bibr">130</xref>]. Taro can be a powerful ally considering its medium glycemic index, since 33% of total taro starch is composed of SDS and RS after cooking, and high dietary fiber content, which are two essential properties to manage these metabolic dysfunctions (
 <xref rid="ijms-22-00265-t001" ref-type="table">Table 1</xref>). Moreover, other taro bioactive molecules can synergistically reinforce the metabolic effects of taro, as demonstrated in preclinical trials (
 <xref ref-type="fig" rid="ijms-22-00265-f003">Figure 3</xref> and 
 <xref rid="ijms-22-00265-t002" ref-type="table">Table 2</xref>).
</p>
